Experience in the medical management of potential laboratory exposures to agents of bioterrorism on the basis of risk assessment at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID)

Journal of Occupational and Environmental Medicine

Volumn 46, Issue 8, 2004, Pages 801-811

  Rusnak, Janice M ^a   Kortepeter, Mark G ^a   Aldis, John ^a   Boudreau, Ellen ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CIDOFOVIR; CIPROFLOXACIN; DOXYCYCLINE; JAPANESE ENCEPHALITIS VACCINE; PLAGUE VACCINE; Q FEVER VACCINE; RIBAVIRIN; SMALLPOX VACCINE; TOXOID; TULAREMIA VACCINE; VACCINE; YELLOW FEVER VACCINE;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL INFECTION; BIOLOGICAL WARFARE; BRUCELLA; BURKHOLDERIA; CHIKUNGUNYA ALPHAVIRUS; CONTROLLED STUDY; COXIELLA BURNETII; EASTERN EQUINE ENCEPHALOMYELITIS VIRUS; ENCEPHALOMYELITIS; EPIDEMIC ENCEPHALITIS; FRANCISELLA TULARENSIS; HEMORRHAGIC FEVER; HORSE DISEASE; HUMAN; JUNIN VIRUS; LABORATORY PERSONNEL; MAJOR CLINICAL STUDY; MILITARY MEDICINE; NEEDLESTICK INJURY; OCCUPATIONAL EXPOSURE; POSTEXPOSURE PROPHYLAXIS; PROTECTIVE EQUIPMENT; Q FEVER; RISK ASSESSMENT; UNITED STATES; VACCINATION; VACCINIA; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS INFECTION; WESTERN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; YERSINIA PESTIS;

ALPHAVIRUS INFECTIONS; ANTHRAX; ANTIBIOTIC PROPHYLAXIS; BACILLUS ANTHRACIS; BIOTERRORISM; CHIKUNGUNYA VIRUS; HUMANS; LABORATORY INFECTION; MILITARY MEDICINE; OCCUPATIONAL EXPOSURE; PLAGUE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; UNITED STATES; VACCINES; YERSINIA PESTIS;

ALPHAVIRUS; ANTHRAX; BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS); BRUCELLA; BURKHOLDERIA; CHIKUNGUNYA VIRUS; COXIELLA BURNETII; EASTERN EQUINE ENCEPHALITIS VIRUS; EQUIDAE; EQUUS CABALLUS; FRANCISELLA TULARENSIS; JAPANESE ENCEPHALITIS VIRUS; JUNIN VIRUS; VARIOLA VIRUS; VENEZUELAN EQUINE ENCEPHALITIS VIRUS; WESTERN EQUINE ENCEPHALOMYELITIS VIRUS; YERSINIA; YERSINIA PESTIS;

EID: 4143129959     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jom.0000135539.99691.4e     Document Type: Article

References (44)

1. Page EH, Martinez KF, Seitz TA, Bernard BP, Tepper AL. Update: cutaneous anthrax in a laboratory worker-Texas, 2002. MMWR. 2003;51:482.
2. Wedum AG. The Detrick experience as a guide to the probable efficacy of P4 microbiological containment facilities for studies on microbial recombinant DNA molecules. J Am Biol Safety Assoc. 1996;1:7-25.
3. US Department of Health and Human Services, Public Health Service, Center for Disease Control, and National Institute of Health. Biosafety in Microbiological and Biomedical Laboratories. 4th ed. Washington, DC: US Government Printing Office; 1999.
4. Wedum AG, Barkley WE, Hellman A. Handling of infectious agents. J Am Vet Med Assoc. 1972;161:1557-1567.
5. Wedum AG II. Airborne infection in the laboratory. Am J Publ Health Nations Health. 1964;54:1669-1673.
6. Barbeito MS, Alg RL, Wedum AG. Infectious bacterial aerosol from dropped Petri dish cultures. Am J Med Technol. 1961;27:318-322.
7. Wedum AG. Control of laboratory airborne infections. Bacteriol Rev. 1961;25:210-216.
8. Wedum AG. Laboratory safety research with infectious aerosols. Public Health Rep. 1964;79:619-633.
9. Kruse RH, Wedum AG. Cross infection with eighteen pathogens among caged laboratory animals. Lab Anim Care. 1970;20:541-560.
10. Wedum AG. Prevention of laboratory-acquired infections. Am J Med Technol. 1956;22:311-315.
11. Wedum AG. Defensive aspects of biological warfare. JAMA. 1956;162:34-37.
12. Hanel E, Miller OT, Phillips GB, Wedum AG. Laboratory design for study of infectious disease. Am J Public Health. 1956;46:1102-1113.
13. Reitman M, Wedum AG. Microbiological safety. Public Health Rep. 1956;71:659-665.
14. Wedum AG. Bacteriological safety. Am J Public Health. 1953;43:1428-1437.
15. Pike RM, Sulkin SE, Schulze ML. Continuing importance of laboratory-acquired infections. Am J Public Health. 1965;55:190-199.
16. Burke DS. Immunization against tularemia: analysis of the effectiveness of live Francisells tularensis vaccine in prevention of laboratory-acquired tularemia. J Infect Dis. 1977;135:55-60.
17. Cieslak TJ, Christopher GW, Kortepeter MG, Rowe JR, Pavlin JA, Culpepper RC. Immunization against potential biological warfare agents. Clin Infect Dis. 2000;20:843-850.
18. Pittman PR, Makuch RS, Magniafico JA, Cannon TL, Gibbs PH, Peters CJ. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine. 1996;36:337-343.
19. Bartelloni PJ, McKinney RW, Duffy TP, Cole FE. An inactivated eastern equine encephalomyelitis vaccine propagated in chick-embryo cell culture. II. Clinical and serologic responses in man. Am J Trop Med Hyg. 1970;19:123-126.
20. Bartelloni PJ. Inactivated western equine encephalomyelitis vaccine propagated in chick embryo cell culture. Clinical and serological evaluation in man. Am J Trop Med Hyg. 1971;20:1446-1449.
21. Pittman PR, Liu CT, Cannon TL, et al. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a twelve-year experience. Vaccine. 1999;18:181-189.
22. Levitt NG, Ramsburh HH, Hasty SE, Repik PM, Cole FE, Lupton H. Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine. 1986;4:157-162.
23. Maiztegui JI, McKee KT, Barrera-Oro JG, et al. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. J Infect Dis. 1998;177:277-283.
24. Kunz C, Heinz FX, Hofmann H. Immunogenicity and reactinogenicity of a highly purified vaccine against tick-borne encephalitis. J Med Virol. 1980;6:103-109.
25. Srinivasan A, Kraus CN, DeShazer D, et al. Glanders in a military research microbiologist. N Engl J Med. 2001;345:256-258.
26. Rusnak JM, Boudreau E, Petit P, Ranadive M, Kortepeter M. An unusual exposure to Bacillus anthracis in a research laboratory. J Occup Environ Med. 2004;46:313-314.
27. Cieslak TJ, Christopher GW, Eitzen EM. The "Slammer": isolation and biocontainment of patients exposed to biosafety level 4 pathogens. Clin Infect Dis. 1999;29:1083.
28. Burke DS, Ramsburg HH, Edelman R. Persistence in humans of antibody to subtypes of Venezuelan equine encephalomyelitis (VEE) virus after immunization with attenuated (TC-83) VEE virus vaccine. J Infect Dis. 1977;136:354-359.
29. McClain, DJ, Pittman PR, Ramsburg HH, et al. Immunologic interference from sequential administration of live attenuated alphavirus vaccines. J Infect Dis. 1998;177:634-641.
30. Chapman LE, Mertz CJ, Jolson HM, et al. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Antivir Ther. 1999;4:211-219.
31. De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 2002;55:1-13.
32. Mempel M, Gisel I, Klugbauer N, et al. Laboratory acquired infection with recombinant vaccinia virus containing an immunomodulating construct. J Invest Dermatol. 2003;120:356-358.
33. Openshaw PF, Alwan WH, Cherrie AH, Reocrod FM. Accidental infection of laboratory worker with recombinant vaccinia virus. Lancet. 1991;338:459.
34. Moussatche N, Tuyama M, Kato SE, et al. Accidental infection of laboratory worker with vaccinia virus. Emerging Infect Dis. 2003;9:724-726.
35. Advisory Committee on Immunization Practices. Use of anthrax vaccine in the United States. MMWR MMWR. 2000;49:1-23.
36. Post-exposure anthrax prophylaxis. Med Lett. 2001;43:91-92.
37. Friedlander AM, Welkos SL, Pitt MLM, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis. 1993;167:1239-1242.
38. Bell DM, Kozarsky PE, Stephens DS. Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax. Emerg Infect Dis. 2002;8:222-225.
39. Brachman PS, Plotkin SA, Bumford FH, Atchison MM. An epidemic of inhalation anthrax: the first in the twentieth century. Am J Hyg. 1960;72:6-23.
40. Russell P, Eley SM, Bell DL, Manchee RJ, Titball RW. Doxycycline or ciprofloxacin against experimental Yesinia pestis infection. J Antimicrob Chemother. 1998;120:156-163.
41. Centers for Disease Control and Prevention. Prevention of plague: recommendations of the advisory committee on immunization practice (ACIP). MMWR. 1996;45:1-15.
42. Sawyer WD, Dangerfield HG, Hogge AL, Crozier D. Antibiotic prophylaxis and therapy of airborne tularemia. Bacteriol Rev. 1966;30:542-548.
43. Tigertt WD, Benenson AS. Studies on Q fever in man. Trans Assoc Am Phys. 1956;69:98-104.
44. Batmanov VP, Ilyukhin VI, Lozovaya NA, Andropova NV. Urgent prophylaxis of experimental melioidosis in white rats. [Abstract no. 61] In: Programs and Abstracts Book of the 2004 ASM Biodefense Research Meeting, Baltimore, MD; 2004:31.